Zymeworks Inc represents values of innovation, collaboration, and scientific excellence. As a biopharmaceutical company, Zymeworks is committed to developing breakthrough therapies to improve the lives of patients. The company's corporate philosophy revolves around leveraging its proprietary drug discovery platform and advanced protein engineering capabilities. By focusing on developing multifunctional therapeutics, Zymeworks aims to address unmet medical needs and deliver transformative treatments in oncology and other disease areas. With a strong emphasis on research and development, Zymeworks strives to revolutionize the field of biotechnology and contribute to advancements in patient care.

Zymeworks Inc is primarily present in several countries and regions. As a global biopharmaceutical company, Zymeworks operates in the United States, Canada, and Europe. With its headquarters based in Vancouver, Canada, Zymeworks has expanded its presence in major pharmaceutical markets, including the United States and various European countries. Being renowned for its innovative drug discovery and development technologies, Zymeworks has established collaborations with partners worldwide, contributing to its international presence and reach within the biopharmaceutical industry.

Zymeworks Inc, a leading biopharmaceutical company, has achieved numerous significant milestones. Over the years, the company has successfully advanced its proprietary Azymetric™ and EFECT™ platforms, revolutionizing the development of bispecific antibodies for various therapeutic areas. Some notable achievements include the partnership with leading pharmaceutical companies, such as Merck and Eli Lilly, for the development of multiple therapies. Zymeworks Inc has also received regulatory approvals and achieved clinical development milestones for its investigational drugs, showcasing its dedication to improving patient care. These milestones underline Zymeworks Inc's commitment to innovation and its relentless pursuit of breakthrough treatments in the field of biopharmaceuticals.

Zymeworks Inc, a leading biopharmaceutical company, was founded in 2003 in Vancouver, Canada. The company specializes in the development of innovative, protein-based therapeutics for the treatment of cancer and other diseases. With a strong focus on antibody engineering, Zymeworks has developed proprietary platforms that enable the design and optimization of therapeutic antibodies. Over the years, Zymeworks has established collaborations with global pharmaceutical companies, leveraging its technology to advance drug discovery and development efforts. With a dedicated team of experts and a robust pipeline of potential therapies, Zymeworks Inc continues to make significant contributions to the field of biopharmaceuticals.

The main competitors of Zymeworks Inc in the market include large pharmaceutical companies such as Amgen, Roche, Novartis, and Bristol-Myers Squibb. These companies are also actively involved in the field of biotechnology and drug development.

Zymeworks Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Zymeworks Inc is focused on the development of multifunctional biotherapeutics using its proprietary Azymetric™ and EFECT™ platforms. The company leverages these platforms to create novel antibody-based drug candidates with enhanced characteristics, such as increased potency and multi-targeting capabilities. Zymeworks aims to address unmet medical needs across various therapeutic areas, including oncology, autoimmune, and inflammatory diseases. By employing its innovative platforms, Zymeworks aims to bring differentiated and effective treatments to patients, while also collaborating with leading biopharmaceutical companies to advance its pipeline.

Raportul Zymeworks preț/beneficiu este -10,70.

Raportul Zymeworks preț/vânzări este 7,72.

Scorul de calitate AlleAktien pentru Zymeworks este 3/10.

Cifra de afaceri a așteptată Zymeworks este de 111,17 milioane USD.

Profitul așteptată Zymeworks este -80,29 milioane USD.

Zymeworks Inc specializes in developing therapeutics for patients with cancer and immune disorders. The company aims to transform the treatment of these patients by using innovative technologies and science to create tailored and precise solutions for their needs. Zymeworks' business model consists of two main divisions - therapeutic development and biotechnology platform development. The company offers various products and services within these divisions. Therapeutic development focuses on developing an innovative oncology portfolio of novel multi-specific antibody fragments. The company's therapeutic products aim to precisely recognize and destroy cancer cells. Currently, the company is working on the development of 6 lead candidates in the preclinical and clinical development phase. An example of this is Novartis' leading product, Kymriah®, which was developed in collaboration with Zymeworks. This product has been approved by the FDA and is now a widely used treatment for specific types of cancer. Platform development involves the artificial evolution of proteins to develop biopharmaceuticals with specific properties in a technically sophisticated manner. Zymeworks' product range is diverse and continuously expanding. In platform development, Zymeworks provides access to various biopharmaceutical expertise, such as protein engineering, fusion design, high-throughput screening, and animal modeling. Building on comprehensive experience and recognized capabilities in protein engineering design, Zymeworks offers a full spectrum of common and innovative biopharmaceutical development technologies. In conclusion, Zymeworks Inc is a company committed to improving the quality of life for patients with cancer and immune disorders. The company is active in therapeutic development through the development of novel multi-specific antibody fragments in the preclinical and clinical development phases. Platform development involves the artificial evolution of proteins to develop biopharmaceuticals with specific properties. The company offers a variety of products and services that are continuously expanding and supports its customers in the development of new and innovative medications. Answer: Zymeworks Inc specializes in developing therapeutics for cancer and immune disorders using innovative technologies and science. They have two main divisions - therapeutic development and biotechnology platform development. They offer various products and services in these areas.

Zymeworks distribuie un dividend de 0 USD în plăți anuale.

Dividenda nu poate fi calculată în prezent pentru Zymeworks sau compania nu distribuie dividende.

Codul ISIN pentru Zymeworks este CA98985W1023.

Codul WKN al Zymeworks este A2DP0F.

Ticker-ul pentru Zymeworks este ZYME.

În ultimele 12 luni, Zymeworks a plătit un dividend în valoare de . Aceasta corespunde unei randamente a dividendului de aproximativ . Pentru următoarele 12 luni, Zymeworks va plăti probabil un dividend de 0 USD.

Randamentul dividendelor pentru Zymeworks este în prezent de .

Zymeworks plătește un dividend trimestrial. Acesta este distribuit în lunile .

Zymeworks a plătit dividende în fiecare an, în ultimii 0 ani.

Pentru următoarele 12 luni se așteaptă dividende în valoare de 0 USD. Acest lucru corespunde unei randamente a dividendelor de 0 %.

Zymeworks este atribuit sectorului 'Sănătate'.

Pentru a primi ultimul dividend de Zymeworks de la 28.09.2024 în valoare de 0 USD, trebuia să deții acțiunea în portofoliu înainte de ziua Ex-Tag de pe 28.09.2024.

Ultima plată a dividendului a fost efectuată la 28.09.2024.

În anul 2023, Zymeworks a distribuit 0 USD sub formă de dividende.

Dividendele de la Zymeworks sunt distribuite în USD.